SAVE 49%: Watch the Eurovision Song Contest from anywhere in the world with ExpressVPN. A

BlackRock Inc. has launched a new climate fund it says will support the transition to a low-carbon economy

TL;DR: As of July 1, you can get the Instabridge eSIM Lifetime Mobile Data Plan

Immediate and targeted methane cuts from the fossil fuel industry could prevent nearly 1 million premature deaths due

LAUSANNE, Switzerland & NEWARK, Calif.--(BUSINESS WIRE)--May 24, 2023--

Apple's latest iPhones and Google's new Pixels all have the same issue: a lack of real innovation. Here's how AI could make phones exciting again.

Shares of GameStop are plunging before the opening bell after the company fired CEO Matthew Furlong, the former Amazon executive that was brought in two years ago to turn the struggling video game retailer around

Most UK companies aren’t setting targets to cut their emissions, putting them on a collision course with increasingly

Meta Platforms Inc. is giving Facebook and Instagram creators a way to make money based on how many

To unlock the Accelerator Takeover Perk in NBA 2K24, players must unlock all nine other Takeover Perks in the game by completing specific on-court objectives.

'Payday 3' developer Starbreeze is working hard to resolve the infrastructure issues.

Our canine companions could soon be enjoying much longer lifespans, if a drug which claims it can extend dogs’ lives eventually gets approved. The drug, made by a tech firm in California, just cleared a vital hurdle to doing just that, after it got partial approval by regulators in the US. Loyal, a San Francisco-based company founded in 2020, has been researching how it can increase dogs’ lifespans – in particular larger breeds, which tend to die younger. Large and “giant” breeds tend to live to between eight and 12 years. Smaller dogs, such as Chihuahuas, can keep going to the ripe old age of 20. Loyal’s main product, the catchily-titled LOY-001, is designed not only to extend dogs’ lives but also maintain their quality of life. Now, it has passed the “reasonable expectation of effectiveness” test, set by regulators at the US’ Food and Drug Administration. Loyal’s chief executive, Celine Halioua, said: "Loyal was founded with the ambitious goal of developing the first drugs to extend healthy lifespan in dogs. "This milestone is the result of years of careful work by the team. We'll continue to work just as diligently to bring this and our other longevity programs through to FDA approval." Selective breeding of dogs has caused higher levels of hormones which help the animals grow faster. That is also believed to reduce their lifespan, the company said. Big dogs tend to have more of this hormone than their smaller counterparts. Animal rights activists are not yet convinced. Some experts fear it will only serve to extend animals’ suffering. Loyal, on the other hand, says the drug aims to treat doggy diseases which are associated with ageing through preventing them, rather than waiting for the animals to get sick before treating them. The company said that the drug could be available to US customers as early as 2026. So that’s plenty of time for walkies between now and then. How to join the indy100's free WhatsApp channel Sign up to our free indy100 weekly newsletter Have your say in our news democracy. Click the upvote icon at the top of the page to help raise this article through the indy100 rankings.